Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1001/jamaneurol.2014.463 http://scihub22266oqcxt.onion/10.1001/jamaneurol.2014.463 C4477824!4477824 !24842754     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24842754 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24842754 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       JAMA+Neurol 2014 ; 71 (7 ): 896-900 Nephropedia Template TP {{tp|p=24842754 |t=2014. Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy |pdf=|usr=}}{{24842754 }} gab.com Text Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy JO: JAMA Neurol http://www.kidney.de/pget.php?&tw=1&pmid=24842754 #FOAvip IMPORTANCE: This observational study describes the efficacy and safety of rituximab in 5 patients with voltage-gated potassium channel (VGKC)-complex/leucine-rich, glioma-inactivated 1 (LGI1) antibody-associated encephalopathy. Rituximab is a monoclonal antibody that targets CD20 and is used to treat other neurologic and nonneurologic diseases. OBSERVATIONS: This case series reports sequential seizure frequencies, modified Rankin Scale scores, and VGKC-complex antibody titers in 5 adult patients (median age, 65 years; range, 48-73 years) treated with rituximab. Median time from symptom onset to rituximab initiation was 414 days (range, 312-851 days). One patient showed a rapid clinical improvement after treatment with rituximab alone and experienced a rituximab-responsive clinical relapse. Another showed possible improvement on neuropsychometric memory indexes after rituximab therapy. In contrast, all patients showed robust responses to treatment with glucocorticoids, intravenous immunoglobulins, and/or plasma exchange at some point in their illness. Treatment with glucocorticoids-less so with intravenous immunoglobulins and plasma exchange-was associated with the most marked reductions in VGKC-complex antibodies. The only patient who did not receive glucocorticoids showed the poorest clinical and serologic responses. CONCLUSIONS AND RELEVANCE: Rituximab was well tolerated in this predominantly older adult patient population and may be an effective option for some patients with LGI1 antibody-associated encephalopathy. Glucocorticoid therapy appears particularly efficacious. Earlier rituximab administration and randomized trials are required to formally assess efficacy. Twit Text FOAVip Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy ????JAMA Neurol http://www.kidney.de/pget.php?&tw=1&pmid=24842754 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24842754 #FOAvip English Wikipedia <ref>{{Cite pmid|24842754 }}</ref> Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy #MMPMID24842754 Irani SR ; Gelfand JM ; Bettcher BM ; Singhal NS ; Geschwind MD JAMA Neurol 2014[Jul]; 71 (7 ): 896-900 PMID24842754 show ga IMPORTANCE: This observational study describes the efficacy and safety of rituximab in 5 patients with voltage-gated potassium channel (VGKC)-complex/leucine-rich, glioma-inactivated 1 (LGI1) antibody-associated encephalopathy. Rituximab is a monoclonal antibody that targets CD20 and is used to treat other neurologic and nonneurologic diseases. OBSERVATIONS: This case series reports sequential seizure frequencies, modified Rankin Scale scores, and VGKC-complex antibody titers in 5 adult patients (median age, 65 years; range, 48-73 years) treated with rituximab. Median time from symptom onset to rituximab initiation was 414 days (range, 312-851 days). One patient showed a rapid clinical improvement after treatment with rituximab alone and experienced a rituximab-responsive clinical relapse. Another showed possible improvement on neuropsychometric memory indexes after rituximab therapy. In contrast, all patients showed robust responses to treatment with glucocorticoids, intravenous immunoglobulins, and/or plasma exchange at some point in their illness. Treatment with glucocorticoids-less so with intravenous immunoglobulins and plasma exchange-was associated with the most marked reductions in VGKC-complex antibodies. The only patient who did not receive glucocorticoids showed the poorest clinical and serologic responses. CONCLUSIONS AND RELEVANCE: Rituximab was well tolerated in this predominantly older adult patient population and may be an effective option for some patients with LGI1 antibody-associated encephalopathy. Glucocorticoid therapy appears particularly efficacious. Earlier rituximab administration and randomized trials are required to formally assess efficacy. |Aged [MESH] |Antibodies, Monoclonal, Murine-Derived/administration & dosage/*pharmacology [MESH] |Antigens, CD20/metabolism [MESH] |Autoantibodies/*biosynthesis/blood [MESH] |Brain Diseases/drug therapy/*immunology [MESH] |Female [MESH] |Humans [MESH] |Immunologic Factors/administration & dosage/*pharmacology [MESH] |Intracellular Signaling Peptides and Proteins [MESH] |Male [MESH] |Middle Aged [MESH] |Potassium Channels, Voltage-Gated/immunology [MESH] |Proteins/*immunology [MESH] |Retrospective Studies [MESH] |Rituximab [MESH] |Severity of Illness Index [MESH]Effect of rituximab in patients with leucine-rich, glioma-inactivated (epmc).pdf DeepDyve Pubget Overpricing